ArticlemSystems2021
Hidden Treasures: Microbial Natural Product Biosynthesis off the Beaten Path.
Article in mSystems, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Genome mining and OSMAC strategies unveil diverse secondary metabolites from the endophytic fungusFrontiers in microbiology · 2025Article
- RAIChU: automating the visualisation of natural product biosynthesis.Journal of cheminformatics · 2024Article
- Bacterial diversity and chemical ecology of natural product-producing bacteria from Great Salt Lake sediment.ISME communications · 2024Article
- Bacterial Diversity and Chemical Ecology of Natural Product-Producing Bacteria from Great Salt Lake Sediment.bioRxiv : the preprint server for biology · 2023Article
- Deciphering chemical logic of fungal natural product biosynthesis through heterologous expression and genome mining.Natural product reports · 2023Review
- Complex peptide natural products: Biosynthetic principles, challenges and opportunities for pathway engineering.Synthetic and systems biotechnology · 2022Article
- Navigating and expanding the roadmap of natural product genome mining tools.Beilstein journal of organic chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Microbes produce structurally diverse natural products to interact with their environment. Many of the biosynthetic products involved in this "metabolic small talk" have been exploited for the treatment of various diseases. As an alternative to the traditional bioactivity-guided workflow, genome mining has been introduced for targeted natural product discovery based on genome sequence information. In this commentary, we will discuss the evolution of genome mining, as well as its current limitations. The Helfrich laboratory aims to play a leading role in overcoming these limitations with the development of computational strategies to identify noncanonical biosynthetic pathways and to decipher the principles that govern the production of the associated metabolites. We will use these insights to develop algorithms for the prediction of natural product scaffolds. These studies will pave the way toward a more comprehensive understanding of the full biosynthetic repertoire encoded in microbial genomes and provide access to novel metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.